MRK

Merck & Co
D

MRK

Arincen67/100B

Merck & Co stock buybacks 1989–2026

Merck & Co spent 653.00M USD buying back its shares in Q3 FY2026, the three months to 30 September 2026, down 50.6% on the same quarter a year before. Merck & Co spent 3.54B USD buying back its shares over the last twelve months, down 18.2% on the twelve months before. In fiscal year 2025 it spent 5.08B USD, up 289.3% on the year before.

Last updated 7 Nov 2026 · Next report 2 Feb 2027

Stock buybacks

Growth

Fiscal yearPeriod endingStock buybacksGrowthDividends paidFree cash flow
TTM30 Sept 20263.54B-18.17%8.37B14.75B
FY202531 Dec 20255.08B+289.28%8.18B12.36B
FY202431 Dec 20241.31B-2.97%7.84B18.10B
FY202331 Dec 20231.35B—7.45B9.14B
FY202231 Dec 20220.00-100.00%7.01B14.71B
FY202131 Dec 2021840.00M-34.43%6.61B9.66B
FY202031 Dec 20201.28B-73.20%6.22B5.82B
FY201931 Dec 20194.78B-47.42%5.70B9.97B
FY201831 Dec 20189.09B+126.48%5.17B8.31B
FY201731 Dec 20174.01B+16.89%5.17B4.56B
FY201631 Dec 20163.43B-17.96%5.12B8.76B
FY201531 Dec 20154.19B-45.66%5.12B11.14B
FY201431 Dec 20147.70B+18.22%5.25B5.54B
FY201331 Dec 20136.52B+151.49%5.28B10.11B
FY201231 Dec 20122.59B+34.88%5.24B8.07B
FY201131 Dec 20111.92B+20.59%4.81B10.66B
FY201031 Dec 20101.59B—4.85B9.14B
FY200931 Dec 20090.00-100.00%3.22B1.93B
FY200831 Dec 20082.73B+90.60%3.28B5.27B
FY200731 Dec 20071.43B+42.64%3.31B5.99B
FY200631 Dec 20061.00B-1.28%3.32B5.79B
FY200531 Dec 20051.02B-58.97%3.35B6.21B
FY200431 Dec 20042.47B+21.66%3.31B7.07B
FY200331 Dec 20032.03B-2.74%3.25B7.95B
FY200231 Dec 20022.09B-46.25%3.19B7.16B
FY200131 Dec 20013.89B+9.74%3.15B6.36B
FY200031 Dec 20003.55B-1.02%2.80B4.96B
FY199931 Dec 19993.58B-1.20%2.59B3.57B
FY199831 Dec 19983.63B+1.48%2.25B3.35B
FY199731 Dec 19973.57B+43.30%2.04B4.87B
FY199631 Dec 19962.49B+58.72%1.73B4.23B
FY199531 Dec 19951.57B+122.98%1.54B1.94B
FY199431 Dec 1994704.50M+89.89%1.43B3.13B
FY199331 Dec 1993371.00M-57.01%1.17B2.04B
FY199231 Dec 1992862.90M+368.71%1.06B1.44B
FY199131 Dec 1991184.10M-75.28%893.20M1.39B
FY199031 Dec 1990744.80M+257.73%749.40M1.38B
FY198931 Dec 1989208.20M—650.30M947.70M

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

The money spent buying back the company's own shares in each period, from the cash flow statement.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow

Common questions about Merck & Co's buybacks

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.